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Abstract
Upon natural infection with pathogens or vaccination, antibodies are produced by a process
called affinity maturation. As affinity maturation ensues, average affinity values between an
antibody and ligand increase with time. Purified antibodies isolated from serum are invari-
ably heterogeneous with respect to their affinity for the ligands they bind, whether macromo-
lecular antigens or haptens (low molecular weight approximations of epitopes on antigens).
However, less is known about how the extent of this heterogeneity evolves with time during
affinity maturation. To shed light on this issue, we have taken advantage of previously pub-
lished data from Eisen and Siskind (1964). Using the ratio of the strongest to the weakest
binding subsets as a metric of heterogeneity (or affinity inequality), we analyzed antibodies
isolated from individual serum samples. The ratios were initially as high as 50-fold, and
decreased over a few weeks after a single injection of small antigen doses to around unity.
This decrease in the effective heterogeneity of antibody affinities with time is consistent with
Darwinian evolution in the strong selection limit. By contrast, neither the average affinity nor
the heterogeneity evolves much with time for high doses of antigen, as competition between
clones of the same affinity is minimal.
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Introduction
The strength of bonds formed by antibodies (Abs) with antigens (Ags) is one of the critical
determinants of immune responses against pathogens. Ags are generally proteins and structur-
ally so complex that much of what was first learned about Ab-Ag bonding, and how that
evolves as affinity maturation ensues, is based upon Ab binding of small molecules that closely
approximate the sites on protein Ags (epitopes) that are recognized by Abs. Called haptens,
these small molecules bind specifically to Ag binding sites but themselves are not immuno-
genic. The strengths of the bonds that haptens form with Abs extend over about a million-fold
range (103 or 104–1010 M-1) [1,2]. This range encompasses the bond strengths measured for
authentic protein Ags binding with Abs—whether monoclonal Abs or average values for het-
erogeneous (polyclonal) populations of purified Abs isolated from serum.
Long before Ab affinity could be measured it was known that immune sera to bacteria, red
blood cells and proteins cross-reacted with structures that resembled the inciting antigen (the
immunogen) and that after adsorption or precipitation of all Abs to cross-reacting (heterolo-
gous) structures, the remaining Abs could still react with the immunogen. These findings were
attributed to a diversity of serum Abs that could react with different components of the com-
plex immunogens. In 1936, however, Landsteiner and van der Scheer showed that antisera
raised against an immunogen having a chemically defined epitope (azophenylsuberanilic acid)
could be exhaustively adsorbed with various cross-reacting alternate forms of the epitope and
the remaining Abs could still react with the homologous epitope; hence their conclusion that
Abs to a singular epitope “are not entirely uniform but vary in specificity to some degree” [3].
Studies of Ab binding to haptens confirmed and extended previous work on more complex
immunogens. Haptens used either to inhibit specific precipitation of Abs from antisera by hap-
tenated Ags (hapten-inhibition) [4], or to bind directly, in absence of any Ag, to purified Abs
[5], demonstrated variability in Ab binding. When ligands were added incrementally to Abs at
a constant concentration in hapten inhibition experiments, the resulting binding curves were
nearly always non-linear, as though apparent equilibrium constants, determined for each
point, decreased with increasing concentration of the ligand. Such non-linearity was attributed
to the variability inherent in the combined free energy of Abs with hapten in heterogeneous
anti-arsanilate antiserum, which could be accounted for by a Gaussian error function [4].
There were misgivings about the quantitative nature of this approach because in hapten-inhibi-
tion of specific precipitation the composition of soluble complexes—of Ab, Ag, and hapten—
were unknown [6]. However, Karush found that there was good agreement between hapten-
Ab interactions measured directly by equilibrium dialysis and the theoretical binding curves
based upon an assumed Gaussian distribution of free energy of hapten-Ab binding [7,8]. Thus
binding of a hapten to a population of cognate Ab molecules isolated from serum could be
characterized by two constants: i) the average bond-strength (K0, the mean equilibrium associ-
ation constant or intrinsic affinity), and ii) an index of heterogeneity with respect to affinity
(sigma, σ).
In response to most immunogens, Abs made initially have low affinity and those made later
have progressively higher affinity [9,10]. This progression, or affinity maturation, arises from
events that take place in germinal centers (GC), small clusters of cells in secondary lymphoid
tissues including lymph nodes, spleen, and Peyer’s patches on intestinal mucosae [11]. Much
of what we know about how processes in GCs lead to higher affinity Abs was learned subse-
quent to the first descriptions of affinity maturation. Each GC is formed by a few antigen (Ag)-
stimulated naïve B cells [12] which, in GC, express the antigen-activated cytidine deaminase,
AID, that causes mutations in the variable regions of the H and L chains of the Ab expressed
by that B cell [13]. The diverse population of B cells thus generated express different Ag-
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binding receptors (BCR). These cells are then selected against the antigen, which is displayed
on follicular dendritic cells (FDC) in the GC [14–16]. Cells with BCRs that have high affinity
for Ag bind it more readily than those with low affinity BCRs and are thus more likely to
receive survival signals [17]. BCRs are also endocytic receptors [18]. Hence, cells with high
affinity BCRs are more capable than those with low affinity BCRs to endocytose the Ag and
present it as peptide-MHC-II complexes. These peptide-MHC-II complexes can engage with T
cell receptors on the surface of cognate CD4 helper T cells in the GC [19]. The different B cells
compete with each other for limiting numbers of T helper cells; B cells that internalize more
antigens have a competitive advantage. Receipt of signals from T helper cells has been shown
to be the key gatekeeper of B cell survival [20]. Inability to bind to Ag sufficiently strongly or
receive T cell help results in apoptosis [21]. A few selected B cells emerge from the GC and dif-
ferentiate into memory cells and antibody-secreting plasma cells, but most are recycled for fur-
ther rounds of mutation and selection [22]. Thus, in vaccinated or infected individuals,
Darwinian evolution occurs in a relatively short time-scale to generate antibodies with increas-
ingly higher affinity as time ensues.
Advances in microscopy of live cells in intact lymph nodes have provided remarkable visu-
alization of the cellular dynamics underlying the evolutionary events in GC [17,20,23]. Implicit
in these observations, and in some of the mathematical models that characterize GC reactions,
is an expectation that the Abs produced in a given immune response evolve over time to
become relatively homogeneous and of high affinity [24–27]. Previously, however, affinity het-
erogeneity was found to increase over time, not to decrease [28]. Resolving this disparity is of
interest as the extent of heterogeneity may have implications for the evolution of cross-reactive
antibodies against highly mutable and persistent virus infections such as HIV-1 and HCV.
To examine the disparity between expected and observed changes in the heterogeneity of
affinity of Abs undergoing affinity maturation, we re-analyzed previously published data of
Eisen and Siskind [28] on the binding of haptens by serum Abs. Our analysis is based on affin-
ity measurements of purified Abs obtained from rabbit sera. The protocol from the original
paper collected sera over several weeks after dosing with a range of the hapten-bearing immu-
nogens and characterized each collected population by average equilibrium constant (K0) and
sips heterogeneity index (a). In view of the overall approximately million-fold range in intrinsic
affinity values measured for Ab-hapten and Ab-Ag reactions in general, our re-analysis
addresses three specific questions. 1. How large is the diversity of Ab affinities, henceforth
referred to as affinity inequality, in bleeds from individual animals or serum pools from a few
individuals (rabbits)? 2. Does affinity inequality change over time after initiation of the
response to the injected Ag? 3. To what extent is inequality affected by the quantity of Ag
introduced?
To measure affinity inequality, we have relied primarily on affinity ratios between the stron-
gest binding 5% and the weakest binding 5% of each purified Ab population. In response to rel-
atively small doses of the immunogen, the heterogeneity indices have been found to increase
over time [29,30]. Eisen and Siskind (26) originally interpreted their observation that heteroge-
neity increases over time to suggest that maintenance of Ab heterogeneity during the immune
response is evolutionarily advantageous. But, we now show here, at low Ag dose, the extent of
heterogeneity changes more slowly than the increase in the average affinity. As a result, the
effective affinity inequality decreases. At high doses of Ag, however, affinity inequality is
greater and more persistent. This finding suggests that, at low Ag dose, the Darwinian evolu-
tion process of affinity maturation is in the strong selection limit, while this is not the case
when Ag dose is high.
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Methods
The data we analyze are drawn from studies in which rabbits were injected with “haptenated”
proteins 2, 4- dinitrophenyl (DNP)-bovine-γ-globulin. The quantities of Ag administered var-
ied from 5mg to 250mg given as a single injection via footpads. Hapten-specific Abs were pre-
cipitated (or adsorbed) from serum by hapten-protein conjugates in which the protein
component differed from (and did not cross-react with) the protein in the immunogen. Puri-
fied Abs recovered from the precipitates (or adsorbates) corresponded generally to 30–90%
of total precipitable Abs in sera. Binding of haptens, ε-DNP-L-lysine, at various concentrations
by fixed amounts of purified Abs were measured by equilibrium dialysis or fluorescence energy
transfer (at 2–30°C).
The average equilibrium constants (K0) were obtained as the reciprocal of the free ligand
concentration when half the Ab binding sites were occupied [4,31]. From titrations of the hap-
ten-Ab binding, an index of heterogeneity with respect to affinity could be obtained from the
generalized adsorption isotherm [6,32]
r
n
¼ ðK0cÞ
a
1þ ðK0cÞa
ð1Þ
or more conveniently when expressed in alternative form [33] as
log
r
n r
 
¼ a logðK0Þ þ a logðcÞ ð2Þ
where r is mols hapten bound per Ab molecule, n is the number of binding sites per Ab mole-
cule of the IgG type (2), c is the free ligand concentration, and a is an index of heterogeneity
with respect to K0 (afﬁnity). By plotting log rnr
 
vs. log(c), the data fall on a straight line whose
slope is a, the Sips index of heterogeneity with respect to K0.
The Sips and Gaussian probability distributions are virtually congruent [32] and affinity
inequality was measured by converting values for the Sips heterogeneity index (a) to sigma (σ),
the corresponding index of heterogeneity of the Gaussian distribution. The conversion was
based upon the assumption that variations in ΔG described by the Sips distribution
NðDGÞ ¼ 1
p
 sinðpaÞe
½ð aRTÞðDG
DGÞ
1þ 2cosðpaÞ e½ð aRTÞðDGDGÞ þ e½ð2aRTÞðDGDGÞ ð3Þ
are equivalent to those described by the Gaussian distribution,
WðDGÞ ¼ 1
s
ﬃﬃﬃ
p
p  e½ðDGDGÞ2=ðRTsÞ2  ð4Þ
when ΔG0, the maximum free energy values for hapten-Ab bonding, are equivalent such that N
(ΔG°) =W(ΔG°), thus satisfying s ¼ 2 ﬃﬃﬃpp ðcotpa=2Þ.
The extent of affinity inequality among Ab subpopulations in each of the purified serum Ab
preparations, which are described by the Gaussian distributions, can be measured as a ratio
between the average bond strength of the strongest 5% subset and that of the weakest 5% sub-
set. For each serum sample with average equilibrium constant (K0) and Gaussian heterogeneity
index (σ), the weighted average of equilibrium binding constant (a) of the weakest 5% Ab was
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calculated as
R a5th percentile
104
aeðaK0Þ
2=s2 daR a5th percentile
104
eðaK0Þ2=s2 da
where Abs with afﬁnity lower than a5th percentile correspond to the lowest 5% of the population.
Similarly, the average of the strongest 5% population was calculated as
R 1010
a95th percentile
aeðaK0Þ
2=s2 da
R 1010
a95th percentile
eðaK0Þ2=s2 da
where Abs with afﬁnity higher than a95th percentile correspond to the highest 5% of the popula-
tion. Equilibrium constants for Ab binding of ligands that most closely approximate the epi-
tope in the immunogen are rarely, if ever, found to be less than 104 M-1 or greater than 1010 M-
1, whether measured with monoclonal Abs or heterogeneous populations of puriﬁed serum
Abs [1,2]. These limits were therefore taken as the boundaries of the truncated Gaussian distri-
bution. The afﬁnity inequalities are essentially unchanged if the boundaries are taken as
103−1010 M-1 instead of 104−1010 M-1. The 5th and the 95th percentiles of each population were
calculated by ﬁrst transforming the truncated Gaussian distribution to its error function, and
then inverting it to calculate the respective percentiles using Matlab software.
Results
Listed in Table 1 are average equilibrium constants (K0) for the binding of various Ab isolates
to ε-DNP-L-lysine. ε-DNP-L-lysine approximates the principal epitope of the relevant immu-
nogen DNP-BGG, bovine-γ-globulin with DNP groups linked to ε-amino groups of multiple
lysine residues. The Abs were isolated from serum obtained at various times (2–8 weeks) from
19 rabbits injected once with various amounts of the immunogen in water-in-oil emulsion as
“incomplete” Freund’s adjuvant. For those that received the smallest dose (5mg, Fig 1A), the
mean affinity (K0) rose progressively and heterogeneity with respect to affinity also increased;
Values of a in the Sips distribution tended to decrease and Gaussian σ to increase. However,
the mean affinity (K0) increased faster. Hence, the coefficient of variance (σ/K0 ratio) decreased
progressively over the 2–8 week period. Correspondingly, the ratios between the strongest and
the weakest binding subsets also decreased: at the earliest time (2 weeks) this ratio was largest
(the highest affinity subsets exhibited13-55-fold higher K0 than that of the weakest subsets)
and it then fell progressively to where at 8 weeks the ratio was close to 1.0. Thus, although the
affinity heterogeneity index (a or σ) tended to increase, affinity inequality decreased over time
indicating a decreasing effective diversity in Abs.
When higher doses (50, 100 or 250mg) of the same immunogen were used to initiate
responses, the mean K0 values were also initially low and affinity heterogeneity values were
high (Table 2). But in contrast to the responses to the 5mg dose, in 13 of 14 rabbits that
received the higher doses, these initial parameters did not change over the 2–8 week period. It
is especially notable that affinity inequality remained high and changed little over at least 8
weeks. It is possible that the one exception, rabbit # 9, may not have received the full 50 mg
dose.
Discussion
In view of the wide (million-fold) range of affinity values and the affinity heterogeneity indi-
ces previously measured for Ab-Ag and Ab-hapten reactions [1,2], one may have expected that
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the affinity values of Abs to a defined epitope, isolated from a given serum sample, would also
extend over a wide range, and indeed they do. But, importantly, the affinity inequality, mea-
sured as the ratio of the strongest and weakest binding Ab subsets, exhibits a somewhat unex-
pected behavior. In a comprehensive set of changes over time in response to various Ag doses,
the affinity of the strongest subset was only about 10-to 30- fold higher than the weakest in
early bleeds taken two weeks after a small dose of Ag injection. This limited inequality then
decreased progressively to the point where at eight weeks after immunization the difference
between these subsets was essentially not detectable. The observed progressive reduction in the
effective affinity inequality is in accord with the view that GC B cells are in competition for lim-
iting amounts of Ag, and evolution occurs in the strong selection limit. Note, however, that
from the data (collected almost 50 years ago) we cannot comment on the evolution of the het-
erogeneity of clones during GC reactions. Following low Ag dose (e.g. 5mg in Table 1, Fig 1A),
B cells with high affinity BCR are preferentially selected over B cells with low affinity BCR to
mature into Ab-secreting plasma cells and memory B cells. For high Ag doses, there is a surfeit
of Ag, and even B cells with low affinity BCR can also be stimulated to internalize sufficient
antigen and receive T cell help from a potentially less limiting amount of cognate T helper
cells. Thus, most B cells can mature into Ab producing plasma cells and memory B cells. High
Ag dose corresponds to conditions of weak selection. While there is a dearth of information on
how the actual levels of Ag on FDC depends upon dose, the two quantities are likely to be
Table 1. Affinity inequality of antibodies after single injection of 5mg dose of the immunogen in rabbits.
Dose
(mg)
RabbitNo. Weeks
fromantigeninjection
Avg.
equilibriumconstant
(K0)(M
-1 X 10^6)
Heterogeneity
index
Coefﬁcient
ofvariation
( sK0)
Average
ofthe lowest
5thpercentile
(M-1 X 10^6)
Average
ofthe
highest
5th
percentile
(M-1 X
10^6)
Afﬁnityinequality
Sips
(a)
(M-1
X
10^6)
Gaussian
(σ*†)(M-1
X 10^6)
5 #1 2 0.60 0.70 1.8 3.0 0.070 3.4 49
" 5 32 0.50 3.5 0.11 27 37 1.4
5 #2 2 1.6 0.70 1.8 1.1 0.15 4.3 29
" 5 27 0.70 1.8 0.067 24 30 1.3
5 #3 2 0.32 0.70 1.8 5.6 0.059 3.2 54
" 5 1.6 0.60 2.6 1.6 0.14 5.5 39
" 8 20 0.30 7.0 0.35 9.9 30 3.0
5 #4 2 1.0 0.80 1.2 1.2 0.10 2.7 27
" 5 5.9 0.60 2.6 0.44 2.2 9.7 4.4
" 8 250 0.30 7.0 0.028 240 260 1.1
5 #5 2 0.78 0.90 0.56 0.72 0.12 1.6 13
" 5 1.5 0.50 3.5 2.4 0.14 7.0 50
" 8 80 0.50 3.5 0.044 75 85 1.1
* σ derived from sips to Gaussian distribution transformation by Karush (1964) equation
† Standard deviation is σ/
ﬃﬃﬃ
2
p
Antibodies were isolated from serum after single injection of 2, 4-DNP-bovine-γ-globulin as incomplete Freund's adjuvant in rabbits. Numbers are rounded
up to two signiﬁcant ﬁgures (except for data from rabbit # 4 at 8 weeks).
doi:10.1371/journal.pone.0139222.t001
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proportional. In Table 1, Table 2 and Fig 1 the dose effect is strikingly clear because the same
Ag was given to all rabbits in the same way.
Though high Ag doses, like those in Table 2, are not now used in clinical vaccines, and rarely
used experimentally, they are nevertheless of interest because they provide a glimpse of the
range of affinities of BCR on the naïve B cells that initially respond to immunogens. Thus in
rabbits that received 100–250mg Ag (Table 2), the affinities of their serum Abs were on average
105 M-1 and ranged from104−105 M-1 at the lower level to106 M-1 at the upper level. Val-
ues in the former range are similar to those reported for IgM monoclonal antibodies whose
intrinsic univalent affinities have been carefully measured [8,34]. These low affinity levels may
well be characteristic of BCRs on the naïve IgM+ naïve B cells that are first activated by immu-
nogens and initiate formation of GC [17,20].
In the haptenated proteins used as immunogens for studies of Ab-hapten interactions and
affinity maturation, there typically are many haptenic groups per protein molecule (e.g.50
DNP groups attached to a protein molecule with70 lysine residues). It has therefore been
suggested that the haptenated epitopes are actually diverse, despite having a common haptenic
group, and that this diversity could account for the affinity heterogeneity observed with a sim-
ple ligand, such as ε-DNP-L-lysine, which only approximates the actual epitopes. This possibil-
ity has been evaluated with an immunogen, ε-41-DNP-ribonuclease, in which the DNP group
was attached to the epsilon amino group of lysine 41; Abs from rabbits immunized with this
mono-epitope Ag were just as heterogeneous with respect to affinity for ε-DNP-L-lysine as
those Abs elicited with conventional haptenated Ags [35]. The Abs elicited with another sin-
gle-epitope immunogen, DNP-lysine attached to the single SH group of papain, were also het-
erogeneous in terms of their diverse L chains, though their affinities were not determined [36].
Fig 1. Mean affinity and Gaussian deviation of antibodies over time. (A) Mean affinity (K0) and Gaussian
deviation (σ) (calculated from Sips to Gaussian transformation, Karush (1964)) of antibodies isolated from
serum 2–8 weeks after injection of 5mg of the immunogen (2,4-DNP-bovine-γ-globulin) as incomplete
Freund's adjuvant in rabbits. (B) As in (A), except 50mg injection dose. (C) As in (A), except 100mg injection
dose. (D) As in (A), except 250mg injection dose.
doi:10.1371/journal.pone.0139222.g001
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Table 2. Affinity inequality of antibodies after injection of high dose of the immunogen in rabbits.
Dose
(mg)
Rabbit
No.
Weeks from
antigen
injection
Avg.
equilibrium
constant (K0)
(M-1 X 10^6)
Heterogeneity index Coefﬁcient of
variation ( sK0)
Average of the
lowest 5th
percentile
(M-1 X 10^6)
Average of the
highest 5th
percentile
(M-1 X 10^6)
Afﬁnity
inequality
Sips(a)
(M-1
X10^6)
Gaussian
(σ*†) (M-1 X
10^6)
50 #6 5 0.21 0.60 2.6 12 0.072 4.4 61
" 8 0.55 0.70 1.8 3.3 0.067 3.4 51
50 #7 2 0.21 0.70 1.8 8.6 0.055 3.1 56
" 5 0.36 0.70 1.8 5.0 0.060 3.2 53
" 8 0.97 0.70 1.8 1.9 0.090 3.7 41
50 #8 2 0.26 0.60 2.6 9.9 0.074 4.4 59
" 5 0.20 0.60 2.6 13 0.072 4.4 61
" 8 1.4 0.50 3.5 2.5 0.14 6.9 49
50 #9 2 0.78 0.90 0.56 0.72 0.12 1.6 13
" 5 2.7 0.90 0.56 0.21 1.9 3.5 1.8
" 8 32 0.80 1.2 0.036 30 34 1.1
50 #10 2 0.28 0.80 1.2 4.1 0.044 2.1 48
" 5 0.20 0.70 1.8 9.0 0.055 3.1 56
100 # 11 2 0.21 0.70 1.8 8.6 0.055 3.1 56
" 5 0.29 0.60 2.6 8.9 0.075 4.5 60
100 #12 2 0.37 0.70 1.8 4.9 0.060 3.2 53
" 5 0.59 0.60 2.6 4.4 0.085 4.7 55
" 8 0.89 0.50 3.5 4.0 0.11 6.4 58
100 #13 2 0.17 0.60 2.6 15 0.071 4.4 62
" 5 0.13 0.60 2.6 20 0.070 4.4 63
" 8 0.23 0.90 0.56 2.4 0.030 1.2 40
100 #14 2 0.87 0.80 1.2 1.3 0.081 2.7 33
" 5 1.0 0.80 1.2 1.2 0.096 2.8 29
" 8 0.55 0.70 1.8 3.3 0.067 3.4 51
100 #15 2 0.26 0.70 1.8 6.9 0.057 3.2 56
" 5 0.19 0.80 1.2 6.1 0.041 2.1 51
" 8 0.37 0.90 0.56 1.5 0.039 1.3 33
250 # 16 2 0.14 0.90 0.56 4.0 0.027 1.1 41
" 5 0.13 0.80 1.2 8.9 0.040 2.1 53
" 8 0.10 0.70 1.8 18 0.052 3.1 60
250 #17 2 0.36 0.90 0.56 1.6 0.039 1.3 33
" 5 0.23 0.70 1.8 7.9 0.056 3.2 57
" 8 0.38 0.90 0.56 1.5 0.040 1.3 33
250 #18 2 0.13 0.80 1.2 8.9 0.040 2.1 53
" 5 0.12 0.80 1.2 9.6 0.039 2.1 54
" 8 0.16 0.70 1.8 11 0.054 3.1 57
250 #19 2 0.26 0.60 2.6 9.9 0.074 4.5 61
" 5 0.19 0.70 1.8 9.5 0.055 3.1 56
" 8 0.11 0.70 1.8 16 0.053 3.1 58
* σ derived from sips to Gaussian distribution transformation by Karush (1964) equation
† Standard deviation is σ/
ﬃﬃﬃ
2
p
Antibodies were isolated from serum after single injection of 2, 4-DNP-bovine-γ-globulin in 50, 100 or 250mg as incomplete Freund's adjuvant in rabbits.
Numbers are rounded up to two signiﬁcant ﬁgures.
doi:10.1371/journal.pone.0139222.t002
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It is important to note that affinity has its limits as a measure of diversity: Ab molecules
with the same affinity for a given ligand could differ markedly in on- and off-rates and have dif-
ferent paratopes and cross-reactivities with structural variants of a ligand. In contrast to the
historic data presented here, which was collected by equilibrium dialysis, recent techniques
such as mutation analyses in Ig genes and Ig repertoire sequencing can trace the breadth of Abs
raised against Ag as the immune response progresses, quantifying how the diversity of muta-
tions correlates with affinity [37]. Thus, the micro-evolution in GC towards less affinity
inequality seen in responses to low Ag dose (Table 1, Fig 1) tells us more about forces driving B
cell selection in GCs than about the extent of cross reactions and protective efficacy of affinity
matured serum Abs. Indeed, the broadly-neutralizing monoclonal Abs, such as VRC01, iso-
lated from persons persistently infected with HIV-1, are widely cross-reactive with structural
variants of the epitope in many different strains of the virus despite being homogenous with
respect to their affinity for a viral epitope [38]. In addition, low intrinsic affinity IgM (immuno-
globulin M), which have ten binding sites per molecule, can bind strongly with high avidity to
Ags that have multiple repeats of closely spaced cognate epitopes as, for example, on pneumo-
coccal polysaccharides and influenza virus hemagglutinin. These IgM Abs have been found to
protect mice against otherwise lethal influenza virus infection [39].
The measure of affinity inequality used here is based upon the assumption that a normal
probability distribution function (Sips or Gaussian) is an apt description of the diversity of
bond-strengths or equilibrium constants that characterize the binding of epitopes by a hetero-
geneous population of Ab molecules isolated from serum by immune precipitation or adsorp-
tion. This assumption is supported by agreement between theoretical curves based upon
normal distribution functions and measured K values [6–8,28]. It does not mean, of course,
that other distribution functions may not also be applicable. However, the only report of non-
Gaussian distributions of which we are aware is based on Ab affinity measurements made with
crude globulin fractions of antisera [40]; the skewed distributions bordering on bimodality
may have been due to low affinity Abs produced by B cells that differentiate into Ab secretors
outside of GCs, or even perhaps to non-Ig proteins in the crude globulin fractions [41].
It may well be that the affinity diversity of the Abs produced by a small number of plasma
cells emerging from a single lymph node or a few GC would not correspond to a normal distri-
bution. Nevertheless, the average affinity values (K0) considered here (Tables 1 and 2, Fig 1)
were obtained by analyzing samples of Ag-specific precipitable Abs that each contained about
1020 ~1021 purified Ab molecules under approximation that all Abs are 7S-IgG. Thus, these
data represent the average of the output of a large number of plasma cells arising from a great
many GCs. Given these conditions, normal distributions (Sips or Gaussian) remain the most
useful means for describing the affinity diversity of serum Abs that recognize a particular
epitope.
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